Of the eight organizations, six were chosen for their novel ideas to help caregivers of people with cancer and certain blood disorders navigate care and treatment, practice self-care and address the needs of specific patient populations, including those at different disease stages. Two nonprofits received funding for their innovative programs that aim to lessen difficulties faced by people with age-related macular degeneration (AMD) while performing activities of daily living, such as managing life at work or home.
The recipient organizations and their respective initiatives include:
Facing Our Risk of
Sick Cells' Sickle Cell Disease Caregiver Help Desk will help identify and close the gap in current resources available to sickle cell disease caregivers to better address their unique needs.
Triage Cancer's Navigating Access and Equality: Providing the Answers that Matter will help blood cancer caregivers navigate complicated financial and legal topics, including health insurance, employment rights, financial strategies and estate planning.
'Now more than ever, it is important that we stand behind these vital patient advocacy organizations working to help close gaps in care, especially as they continue to navigate the many additional challenges facing patients and caregivers as a result of the COVID-19 pandemic,' said
Two external review committees reviewed the STEP Program proposals, with one committee focused on proposals about caregivers of cancer and certain blood disorders, and one dedicated to AMD submissions. The committees were comprised of experts in a variety of fields such as oncologic and ophthalmic nursing, behavioral health, human resources, optometry, psychology, advocacy, and health disparities. Additionally, individuals impacted by the diseases served on each review committee to ensure different perspectives were represented in the assessment process.
Disclaimer
This media update contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as 'potential,' 'can,' 'will,' 'plan,' 'may,' 'could,' 'would,' 'expect,' 'anticipate,' 'seek,' 'look forward,' 'believe,' 'committed,' 'investigational,' 'pipeline,' 'launch,' or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this media update, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this media update will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in
About Novartis
Located in
Contact:
Tel: +1 862 579 8456
Email: julie.masow@novartis.com
(C) 2021 Electronic News Publishing, source